Search - tctmd.com

Displaying 1 - 20 of 706

Sort: Relevancy | Date

Presentation

TAVR in Pure Native Aortic Valve Regurgitation (AR)

November 30, 2017

Presentation Cardiovascular Interventions 2017

How Me The Data: Key Clinical Trials of 2017

Presenter: Curtiss T. Stinis

November 09, 2017

Presentation Cardiovascular Interventions 2017

TAVR Tips and Tricks: How to Succeed with Challenging Cases

Presenter: Curtiss T. Stinis

November 08, 2017

Presentation TCT 2017

FORMA: 30-Day Outcomes of Transcatheter TV Repair in Patients With Severe Secondary Tricuspid Regurgitation

Presenter: Martin B. Leon, Susheel K. Kodali

November 02, 2017

Presentation TCT 2017

TRI-REPAIR: 30-Day Outcomes of Transcatheter TV Repair in Patients With Severe Secondary Tricuspid Regurgitation

Presenter: Martin B. Leon, Georg Nickenig

November 02, 2017

Presentation TCT 2017

PREVAIL: 5-Year Outcomes From a Randomized Trial of Left Atrial Appendage Closure vs Medical Therapy in Patients With Nonvalvular Atrial Fibrillation

Presenter: Saibal Kar

November 02, 2017

Presentation TCT 2017

Adjunctive Pharmacotherapy During and After TAVR: Current Trends, New Studies, and the Case for Short-term (3-6 months) Systemic Anticoagulation

Presenter: Eberhard Grube, James B. Hermiller Jr., Pascal Vranckx

November 01, 2017

Presentation TCT 2017

A Primer of Conduction Abnormalities after TAVR: Frequency, Clinical Consequences, and Revised Management Recommendations (New Permanent Pacemakers)

Presenter: Eberhard Grube, James B. Hermiller Jr., Hemal Gada

November 01, 2017

Presentation TCT 2017

Hemodynamic Trends on Serial Echocardiograms after TAVR: Comprehensive 5-Year Analyses From PARTNER

Presenter: Pamela S. Douglas

November 01, 2017

Presentation TCT 2017

PFO Closure for Hypoxemia: Who Responds and Who Does Not? Designing a Trial to Prove the Concept

Presenter: Mark Reisman, Brian K. Whisenant, Joseph Kay

November 01, 2017

Presentation TCT 2017

Valve Durability after TAVR: Definitions, Surgical Valve Predicates, and Review of Available Data

Presenter: Danny Dvir

November 01, 2017

Presentation TCT 2017

PFO Closure for Migraine: Dead, Alive, or in Need of Another Trial?

Presenter: Mark Reisman, Brian K. Whisenant, Robert J. Sommer

November 01, 2017

Presentation TCT 2017

The Clinical Relevance of Valve Leaflet Thickening after TAVR

Presenter: Raj Makkar

November 01, 2017

Presentation TCT 2017

Update on the Harmony Transcatheter PV and Other TPV Products Inside and OUS for Severe PR

Presenter: Elchanan Bruckheimer, Doff B. McElhinney, Lee N. Benson

November 01, 2017

Presentation TCT 2017

VTE and PFO Closure: Device? Anticoagulation? Both?

Presenter: Mark Reisman, Brian K. Whisenant, Christian Spies

November 01, 2017

Presentation TCT 2017

Underutilization of TAVR in Minority Populations: Scope, Etiologies, and Possible Solutions

Presenter: Eberhard Grube, James B. Hermiller Jr., Oluseun Alli

November 01, 2017

Presentation TCT 2017

How to Treat Severe PR in the Large RVOT Using Melody or Sapien Valves

Presenter: Elchanan Bruckheimer, Doff B. McElhinney, Daniel S Levi

November 01, 2017

Presentation TCT 2017

When to Refer Your Patient With Severe PR After Surgical TAP

Presenter: Elchanan Bruckheimer, Doff B. McElhinney, Harsimran Sachdeva Singh

November 01, 2017

Presentation TCT 2017

Shared Decision-making is an Essential Component of the Modern-era Heart Team: Rationale and Integration with TAVR Clinical Practice

Presenter: Eberhard Grube, James B. Hermiller Jr., Megan Coylewright

November 01, 2017

Presentation TCT 2017

Complications During and After PFO Closure, Case #3: Arrhythmias

Presenter: John F. Rhodes, Robert J. Sommer

November 01, 2017

Advertisement

TAVR in Pure Native Aortic Valve Regurgitation (AR)

How Me The Data: Key Clinical Trials of 2017

TAVR Tips and Tricks: How to Succeed with Challenging Cases

FORMA: 30-Day Outcomes of Transcatheter TV Repair in Patients With Severe Secondary Tricuspid Regurgitation

TRI-REPAIR: 30-Day Outcomes of Transcatheter TV Repair in Patients With Severe Secondary Tricuspid Regurgitation

PREVAIL: 5-Year Outcomes From a Randomized Trial of Left Atrial Appendage Closure vs Medical Therapy in Patients With Nonvalvular Atrial Fibrillation

Adjunctive Pharmacotherapy During and After TAVR: Current Trends, New Studies, and the Case for Short-term (3-6 months) Systemic Anticoagulation

A Primer of Conduction Abnormalities after TAVR: Frequency, Clinical Consequences, and Revised Management Recommendations (New Permanent Pacemakers)

Hemodynamic Trends on Serial Echocardiograms after TAVR: Comprehensive 5-Year Analyses From PARTNER

PFO Closure for Hypoxemia: Who Responds and Who Does Not? Designing a Trial to Prove the Concept

Valve Durability after TAVR: Definitions, Surgical Valve Predicates, and Review of Available Data

PFO Closure for Migraine: Dead, Alive, or in Need of Another Trial?

The Clinical Relevance of Valve Leaflet Thickening after TAVR

Update on the Harmony Transcatheter PV and Other TPV Products Inside and OUS for Severe PR

VTE and PFO Closure: Device? Anticoagulation? Both?

Underutilization of TAVR in Minority Populations: Scope, Etiologies, and Possible Solutions

How to Treat Severe PR in the Large RVOT Using Melody or Sapien Valves

When to Refer Your Patient With Severe PR After Surgical TAP

Shared Decision-making is an Essential Component of the Modern-era Heart Team: Rationale and Integration with TAVR Clinical Practice

Complications During and After PFO Closure, Case #3: Arrhythmias

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content